

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MedSci Healthcare Holdings Limited

梅斯健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2415)

CHANGE OF DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of MedSci Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 25 September 2024:

- (i) Mr. Fan Jie (“**Mr. Fan**”) has resigned as an executive Director;
- (ii) Mr. Hu Xubo (“**Mr. Hu**”) has resigned as a non-executive Director;
- (iii) Mr. Cheng Liang (“**Mr. Cheng**”) has been appointed as an executive Director; and
- (iv) Ms. Wang Xin (“**Ms. Wang**”) has been appointed as a non-executive Director.

RESIGNATION OF DIRECTORS

The Board announces that with effect from 25 September 2024, Mr. Fan has resigned as executive Director and Mr. Hu has resigned as non-executive Director due to their personal work assignments.

Each of Mr. Fan and Mr. Hu has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation as Director that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board would like to express its sincere gratitude to each of Mr. Fan and Mr. Hu for his valuable contribution to the Company during his tenure in office.

APPOINTMENT OF DIRECTORS

The Board announces that with effect from 25 September 2024, Mr. Cheng has been appointed as an executive Director and Ms. Wang has been appointed as a non-executive Director.

The biographical details of Mr. Cheng and Ms. Wang are set out below:

Mr. Cheng

Mr. Cheng, aged 42, joined the Group in June 2020. Mr. Cheng has been the chief operating officer of the Group and is primarily responsible for the legal compliance and strategic cooperation of the Group since July 2024. Prior to that, Mr. Cheng worked as the development director from June 2020 to December 2022 and the vice president from January 2023 to July 2024, and was primarily responsible for the Group's government affairs, intellectual property rights and external strategic cooperation, and the Group's external strategic cooperation, government affairs, intellectual property rights, legal and compliance matters respectively.

Prior to joining the Group, Mr. Cheng served as a customer executive at Uniland Consulting (Shanghai) Co., Ltd.* (優利諮詢(上海)有限公司), an entity principally engaged in outsourcing information technology services, from July 2004 to June 2005, and a customer manager from June 2005 to December 2006, and he was primarily responsible for providing customer service and management. During the period from January 2007 to July 2007 and from August 2007 to July 2009, Mr. Cheng was a consulting manager and a senior consulting manager at Livingston Market Consultants* (上海歐逸市場行銷顧問有限公司), an entity principally engaged in providing consulting services in the FMCG and pharmaceutical industries, where he was primarily responsible for the management and execution of consulting projects, client-needs analysis, programme development and team coordination, respectively. Mr. Cheng held the position as a key customer manager at Dabang (Shanghai) Management Co., Ltd.* (達邦(上海)管理有限公司), an entity principally engaged in providing communications and public relations services, from August 2009 to July 2011, and he was mainly responsible for customer relationship management, market development, team management and business execution. During the period from August 2011 to February 2014 and from March 2014 to December 2016, Mr. Cheng was a research director and management director at Haier Asia International* (海爾亞洲國際株式會社), an entity principally engaged in operating brands under Haier in Japan and Southeast Asia, and was mainly responsible for execution of company strategy, team management, business operations and customer relationship management, respectively. Mr. Cheng also served as the deputy general manager at Shanghai Shuyue Life Trading Co., Ltd.* (舒悦生活), an entity principally engaged in the sales of shoes, from March 2017 to June 2020, and was mainly responsible for brand strategy development and brand assets management.

Mr. Cheng is currently a member of the International Management Consulting Association and a National Certified Management Consultant in China.

Mr. Cheng received a bachelor's degree in management and a master's degree in business administration for senior management from Shanghai Jiao Tong University (上海交通大學) in July 2004 and July 2017, respectively.

Pursuant to the service agreement entered into between the Company and Mr. Cheng, Mr. CHENG will be appointed for a term of three years commencing from 25 September 2024. Mr. Cheng is entitled to a remuneration of RMB802,500 per annum, subject to any adjustment as may be made by the remuneration committee of the Board or the Board based on the respective responsibilities and performance of Mr. Cheng. Mr. Cheng may also receive discretionary bonus which will be determined by reference to the operating results of the Company and individual performance. The remuneration of Mr. Cheng was determined taking into account his duties and responsibilities and prevailing market standards.

Ms. Wang

Ms. Wang, aged 40, has around 12 years of experience in equity investment. She has been serving as an executive director of Qiming Venture Partners* (啟明創投), a venture capital firm, since March 2012.

Ms. Wang also served as a manager at Egon Zehnder International Ltd.* (億康先達國際人力資源顧問股份有限公司), an entity principally engaged in executive recruitment and leadership consulting, from July 2008 to May 2010, and she was primarily responsible for providing executive recruitment services for Chinese financial institutes. During the period from September 2006 to July 2008, Ms. Wang was a reporter at Agence France-Presse, Shanghai branch, a global news agency.

Ms. Wang obtained a bachelor's degree in broadcasting and television journalism (廣播電視新聞學士) from Fudan University (復旦大學) and a master's degree in business administration from China Europe International Business School (中歐國際工商學院) in July 2006 and March 2012, respectively.

Pursuant to the service agreement entered into between the Company and Ms. Wang, Ms. Wang will be appointed for a term of three years commencing from 25 September 2024. Ms. Wang is not entitled to director's fee, subject to any adjustment as may be made by the remuneration committee of the Board or the Board based on the respective responsibilities and performance of Ms. Wang. Ms. Wang may also receive discretionary bonus which will be determined by reference to the operating results of the Company and individual performance. The remuneration of Ms. Wang was determined taking into account her duties and responsibilities and prevailing market standards.

Save as disclosed above, as at the date of this announcement, each of Mr. Cheng and Ms. Wang did not (1) hold any other positions with the Company or other members of the Group; (2) have any relationships with any directors, senior management or substantial or controlling shareholders of the Company; (3) have any interests in shares of the Company and associated corporation of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)); (4) hold any directorships in the last three years in any public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (5) have any other information that needs to be disclosed pursuant to any of the requirements as set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there is no other matter that need to be brought to the attention of the shareholders of the Company.

By order of the Board
MedSci Healthcare Holdings Limited
梅斯健康控股有限公司

Dr. Zhang Fabao
Chairman of the Board and Executive Director

Hong Kong, 25 September 2024

As at the date of this announcement, the Board of Directors comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Wang Shuai and Mr. Cheng Liang as executive Directors; Ms. Wang Xin and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.

* *for identification purpose only.*